Advertisement

Effect of Bleeding Risk on Type of Stent Used in Patients Presenting With Acute Coronary Syndrome

      Patients at high bleeding risk (HBR) are at increased risk of bleeding following percutaneous coronary intervention (PCI) with drug-eluting stents (DES) due to the need for longer dual antiplatelet duration. We sought to evaluate the likelihood of receiving DES during PCI in HBR populations and to characterize DES utilization trends over time. Consecutive patients who underwent PCI from April 2003 to September 2015 were identified. HBR is defined as patients fulfilling 1 or more of the HBR criteria: age ≥75 years, anticoagulation use at discharge, history of stroke, cancer in previous 3 years, glucocorticoid use, hemoglobin (Hgb) <11 g/dl, platelet count <100,000/mm3, or creatinine clearance (CCr) <40 ml/min. Multivariate analysis was performed to identify which variables predicted DES selection. There were 10,594 patients (41.6%) who the met HBR definition. When adjusting for known risk factors, HBR patients were less likely to receive a DES compared with non-HBR patients (odds ratio [OR] 0.58, 95% confidence interval [CI] 0.54 to 0.62, p <0.001). A preprocedural Hgb <11 g/dl had the greatest association with choosing DES during PCI (OR 0.51, 95% CI 0.45 to 0.57, p <0.001). Within the HBR patients, having 3 or more HBR criteria versus <3 HBR criteria had lower likelihood of receiving a DES (OR 0.50, 95% CI 0.44 to 0.57, p <0.001). In conclusion, presence of HBR has a significant impact upon the decision to use DES.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Levine G.N.
        • Bates E.R.
        • Bittl J.A.
        • Brindis R.G.
        • Fihn S.D.
        • Fleisher L.A.
        • Granger C.B.
        • Lange R.A.
        • Mack M.J.
        • Mauri L.
        • Mehran R.
        • Mukherjee D.
        • Newby L.K.
        • O'Gara P.T.
        • Sabatine M.S.
        • Smith P.K.
        • Smith Jr, S.C.
        2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines.
        J Am Coll Cardiol. 2016; 68: 1082-1115
        • Windecker S.
        • Kolh P.
        • Alfonso F.
        • Collet J.P.
        • Cremer J.
        • Falk V.
        • Filippatos G.
        • Hamm C.
        • Head S.J.
        • Juni P.
        • Kappetein A.P.
        • Kastrati A.
        • Knuuti J.
        • Landmesser U.
        • Laufer G.
        • Neumann F.J.
        • Richter D.J.
        • Schauerte P.
        • Sousa Uva M.
        • Stefanini G.G.
        • Taggart D.P.
        • Torracca L.
        • Valgimigli M.
        • Wijns W.
        • Witkowski A.
        • Authors/Task Force members
        2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
        Eur Heart J. 2014; 35: 2541-2619
        • Feres F.
        • Costa R.A.
        • Abizaid A.
        • Leon M.B.
        • Marin-Neto J.A.
        • Botelho R.V.
        • King 3rd, S.B.
        • Negoita M.
        • Liu M.
        • de Paula J.E.
        • Mangione J.A.
        • Meireles G.X.
        • Castello Jr, H.J.
        • Nicolela Jr, E.L.
        • Perin M.A.
        • Devito F.S.
        • Labrunie A.
        • Salvadori Jr, D.
        • Gusmao M.
        • Staico R.
        • Costa Jr, J.R.
        • de Castro J.P.
        • Abizaid A.S.
        • Bhatt D.L.
        • OPTIMIZE Trial Investigators
        Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
        JAMA. 2013; 310: 2510-2522
        • Stone G.W.
        • Rizvi A.
        • Newman W.
        • Mastali K.
        • Wang J.C.
        • Caputo R.
        • Doostzadeh J.
        • Cao S.
        • Simonton C.A.
        • Sudhir K.
        • Lansky A.J.
        • Cutlip D.E.
        • Kereiakes D.J.
        • SPIRIT IV Investigators
        Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
        N Engl J Med. 2010; 362: 1663-1674
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • Montalescot G.
        • Ruzyllo W.
        • Gottlieb S.
        • Neumann F.J.
        • Ardissino D.
        • De Servi S.
        • Murphy S.A.
        • Riesmeyer J.
        • Weerakkody G.
        • Gibson C.M.
        • Antman E.M.
        • TRITON-TIMI 38 Investigators
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Urban P.
        • Meredith I.T.
        • Abizaid A.
        • Pocock S.J.
        • Carrie D.
        • Naber C.
        • Lipiecki J.
        • Richardt G.
        • Iniguez A.
        • Brunel P.
        • Valdes-Chavarri M.
        • Garot P.
        • Talwar S.
        • Berland J.
        • Abdellaoui M.
        • Eberli F.
        • Oldroyd K.
        • Zambahari R.
        • Gregson J.
        • Greene S.
        • Stoll H.P.
        • Morice M.C.
        • LEADERS FREE Investigators
        Polymer-free drug-coated coronary stents in patients at high bleeding risk.
        N Engl J Med. 2015; 373: 2038-2047
        • Ariotti S.
        • Adamo M.
        • Costa F.
        • Patialiakas A.
        • Briguori C.
        • Thury A.
        • Colangelo S.
        • Campo G.
        • Tebaldi M.
        • Ungi I.
        • Tondi S.
        • Roffi M.
        • Menozzi A.
        • de Cesare N.
        • Garbo R.
        • Meliga E.
        • Testa L.
        • Gabriel H.M.
        • Ferlini M.
        • Vranckx P.
        • Valgimigli M.
        • ZEUS Investigators
        Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS trial.
        JACC Cardiovasc Interv. 2016; 9: 426-436
        • Levine G.N.
        • Bates E.R.
        • Blankenship J.C.
        • Bailey S.R.
        • Bittl J.A.
        • Cercek B.
        • Chambers C.E.
        • Ellis S.G.
        • Guyton R.A.
        • Hollenberg S.M.
        • Khot U.N.
        • Lange R.A.
        • Mauri L.
        • Mehran R.
        • Moussa I.D.
        • Mukherjee D.
        • Nallamothu B.K.
        • Ting H.H.
        2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
        Circulation. 2011; 124: 2574-2609
        • Kirtane A.J.
        • Gupta A.
        • Iyengar S.
        • Moses J.W.
        • Leon M.B.
        • Applegate R.
        • Brodie B.
        • Hannan E.
        • Harjai K.
        • Jensen L.O.
        Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.
        Circulation. 2009; 119: 3198-3206
        • Garot P.
        • Morice M.C.
        • Tresukosol D.
        • Pocock S.J.
        • Meredith I.T.
        • Abizaid A.
        • Carrie D.
        • Naber C.
        • Iniguez A.
        • Talwar S.
        • Menown I.B.
        • Christiansen E.H.
        • Gregson J.
        • Copt S.
        • Hovasse T.
        • Lurz P.
        • Maillard L.
        • Krackhardt F.
        • Ong P.
        • Byrne J.
        • Redwood S.
        • Windhovel U.
        • Greene S.
        • Stoll H.P.
        • Urban P.
        • LEADERS FREE Investigators
        Two-year outcomes of high bleeding risk patients after polymer-free drug-coated stents.
        J Am Coll Cardiol. 2017; 69: 162-171
        • Pfisterer M.
        • Brunner-La Rocca H.P.
        • Buser P.T.
        • Rickenbacher P.
        • Hunziker P.
        • Mueller C.
        • Jeger R.
        • Bader F.
        • Osswald S.
        • Kaiser C.
        Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
        J Am Coll Cardiol. 2006; 48: 2584-2591
        • Valgimigli M.
        • Patialiakas A.
        • Thury A.
        • McFadden E.
        • Colangelo S.
        • Campo G.
        • Tebaldi M.
        • Ungi I.
        • Tondi S.
        • Roffi M.
        • Menozzi A.
        • de Cesare N.
        • Garbo R.
        • Meliga E.
        • Testa L.
        • Gabriel H.M.
        • Airoldi F.
        • Ferlini M.
        • Liistro F.
        • Dellavalle A.
        • Vranckx P.
        • Briguori C.
        • ZEUS Investigators
        Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
        J Am Coll Cardiol. 2015; 65: 805-815
        • Subherwal S.
        • Bach R.G.
        • Chen A.Y.
        • Gage B.F.
        • Rao S.V.
        • Newby L.K.
        • Wang T.Y.
        • Gibler W.B.
        • Ohman E.M.
        • Roe M.T.
        • Pollack Jr, C.V.
        • Peterson E.D.
        • Alexander K.P.
        Baseline risk of major bleeding innon-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score.
        Circulation. 2009; 119: 1873-1882
        • Mehran R.
        • Pocock S.J.
        • Nikolsky E.
        • Clayton T.
        • Dangas G.D.
        • Kirtane A.J.
        • Parise H.
        • Fahy M.
        • Manoukian S.V.
        • Feit F.
        • Ohman M.E.
        • Witzenbichler B.
        • Guagliumi G.
        • Lansky A.J.
        • Stone G.W.
        A risk score to predict bleeding in patients with acute coronary syndromes.
        J Am Coll Cardiol. 2010; 55: 2556-2566
        • Lip G.Y.
        • Frison L.
        • Halperin J.L.
        • Lane D.A.
        Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
        J Am Coll Cardiol. 2011; 57: 173-180
        • Spertus J.A.
        • Kettelkamp R.
        • Vance C.
        • Decker C.
        • Jones P.G.
        • Rumsfeld J.S.
        • Messenger J.C.
        • Khanal S.
        • Peterson E.D.
        • Bach R.G.
        Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement results from the PREMIER registry.
        Circulation. 2006; 113: 2803-2809
        • Hofma S.H.
        • Brouwer J.
        • Velders M.A.
        • van't Hof A.W.
        • Smits P.C.
        • Quere M.
        • de Vries C.J.
        • van Boven A.J.
        Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
        J Am Coll Cardiol. 2012; 60: 381-387
        • Onuma Y.
        • Miquel-Hebert K.
        • Serruys P.W.
        • SPIRIT II Investigators
        Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
        EuroIntervention. 2013; 8: 1047-1051
        • Pilgrim T.
        • Vetterli F.
        • Kalesan B.
        • Stefanini G.G.
        • Raber L.
        • Stortecky S.
        • Gloekler S.
        • Binder R.K.
        • Wenaweser P.
        • Moschovitis A.
        • Khattab A.A.
        • Buellesfeld L.
        • Zwahlen M.
        • Meier B.
        • Juni P.
        • Windecker S.
        The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents.
        Circ Cardiovasc Interv. 2012; 5: 202-210
        • Rubboli A.
        • Kovacic J.C.
        • Mehran R.
        • Lip G.Y.
        Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options.
        Chest. 2011; 139: 981-987
        • Raber L.
        • Kelbaek H.
        • Taniwaki M.
        • Ostojic M.
        • Heg D.
        • Baumbach A.
        • von Birgelen C.
        • Roffi M.
        • Tuller D.
        • Engstrom T.
        • Moschovitis A.
        • Pedrazzini G.
        • Wenaweser P.
        • Kornowski R.
        • Weber K.
        • Luscher T.F.
        • Matter C.M.
        • Meier B.
        • Juni P.
        • Windecker S.
        • COMFORTABLE AMI Trial Investigators
        Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial.
        Circ Cardiovasc Interv. 2014; 7: 355-364
        • Tandjung K.
        • Sen H.
        • Lam M.K.
        • Basalus M.W.
        • Louwerenburg J.H.
        • Stoel M.G.
        • van Houwelingen K.G.
        • de Man F.H.
        • Linssen G.C.
        • Said S.A.
        • Nienhuis M.B.
        • Lowik M.M.
        • Verhorst P.M.
        • van der Palen J.
        • von Birgelen C.
        Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
        J Am Coll Cardiol. 2013; 61: 2406-2416
        • Kappetein A.P.
        • Feldman T.E.
        • Mack M.J.
        • Morice M.C.
        • Holmes D.R.
        • Stahle E.
        • Dawkins K.D.
        • Mohr F.W.
        • Serruys P.W.
        • Colombo A.
        Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial.
        Eur Heart J. 2011; 32: 2125-2134
        • Kaiser C.
        • Galatius S.
        • Erne P.
        • Eberli F.
        • Alber H.
        • Rickli H.
        • Pedrazzini G.
        • Hornig B.
        • Bertel O.
        • Bonetti P.
        • De Servi S.
        • Brunner-La Rocca H.P.
        • Ricard I.
        • Pfisterer M.
        • BASKET–PROVE Study Group
        Drug-eluting versus bare-metal stents in large coronary arteries.
        N Engl J Med. 2010; 363: 2310-2319
      1. EVOLVE Short DAPT Study.
        (Available at)